The Effects of Programmed Death-ligand 1 on Postoperative Pain for Lung Cancer Patients

NCT06503432 | Recruiting

• 1 other identifier: 2020PHB252-01
• Study Type: observational
• Target: 100
• Locations: 1 country
• Sites: 1

Brief Summary

The concentration of plasma programmed death-ligand 1(PD-L1) for lung cancer patients before video-assisted thoracoscopic surgery is detected. According to the distribution of plasma concentration, patients are divided into high or low expression of PD-L1. Differences in acute and chronic postoperative pain are compared between two groups of patients. And effects of PD-L1 expresion on postoperative pain in lung cancer patients are explained.

Conditions

Lung Cancer; Postoperative Pain

Outcome Measures

Primary Outcomes (1)

• the incidence of chronic pain after surgery

  Patients were followed up by the Brief Pain Inventory questionnaire about the details of chronic pain.

  3 months after surgery

Study Arms (2)

high expression of programmed death-ligand 1

According to the distribution of PD-L1 concentration levels in the plasma, participants were divided into two groups: high expression of PD-L1 (PD-L1(H)) and low expression of PD-L1 (PD-L1(L)).

low expression of programmed death-ligand 1

According to the distribution of PD-L1 concentration levels in the plasma, participants were divided into two groups: high expression of PD-L1 (PD-L1(H)) and low expression of PD-L1 (PD-L1(L)).

Eligibility Criteria

• Age: 18 Years - 80 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Patients underwent video-assisted thoracoscopic surgery for malignant lung disease.

You may qualify if:

• American Society of Anesthesiologists physical status I-IV (males and females).
• years of age.
• Patients undergoing video-assisted thoracoscopic surgery for malignant lung disease.

You may not qualify if:

• History of opioid abuse.
• Known psychiatric disorders.
• Unexpected conversion to thoracotomy or transferred to intensive care unit for further treatment.
• Combined with other surgeries or sites.

Sponsors & Collaborators

• Peking University People's Hospital: lead

Study Sites (1)

Peking University People's Hospital

Beijing, Beijing Municipality, 100037, China

RECRUITING

MeSH Terms

Conditions

Lung Neoplasms; Pain, Postoperative

Condition Hierarchy (Ancestors)

Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Neoplasms; Lung Diseases; Respiratory Tract Diseases; Postoperative Complications; Pathologic Processes; Pathological Conditions, Signs and Symptoms; Pain; Neurologic Manifestations; Signs and Symptoms

Study Officials

• Xue Tian, MD

  Peking University People's Hospital

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Xue Tian, MD

CONTACT

88325581; justine_troy@163.com

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: director of department of Anesthesiology and Pain medicine

Study Record Dates

• First Submitted: June 26, 2024
• First Posted: July 16, 2024
• Study Start: July 20, 2024
• Primary Completion: February 1, 2025
• Study Completion: March 1, 2025
• Last Updated: September 19, 2024

Record last verified: 2024-06

Locations

CN (1)